snd-919

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Pramipexole dihydrochloride hydrate (Standard) is a reference standard of Pramipexole dihydrochloride hydrate intended for quantitative analysis, quality control, and related biochemical research applications.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Pramipexole dihydrochloride could be used to treat Parkinson disease.

Dexpramipexole ((R)-Pramipexole), a BTZ structural analog of riluzole, is a mitochondrial protectant that maintains mitochondrial function and energy production, attenuates myocardial ischemia/reperfusion injury by up-regulating mitochondrial autophagy, and can be used in the treatment of amyotrophic lateral sclerosis disease.

Dexpramipexole dihydrochloride (KNS-760704 dihydrochloride) ((R)-Pramipexole dihydrochloride) is a neuroprotective agent and is a weak non-ergoline dopamine agonist.

(S)-Pramipexole-(N-Propyl-2,2,3,3,3-D5) Dihydrochloride is a deuterated compound of  (S)-Pramipexole Dihydrochloride (T1476L). (S)-Pramipexole Dihydrochloride has a CAS number of 104632-25-9. Pramipexole dihydrochloride could be used to treat Parkinson disease.